The data highlight emerging evidence that Opus Genetics’ gene therapy OPGx-LCA5 may restore daytime vision mediated by cones in pediatric patients with severe, early-onset disease, while also ...

The results, published May 5 in Nature Genetics, offer a new way to understand the molecular roots of cancer — an especially ...

Target Enrollment Achieved with the Inclusion of Participants with Both Dominant and Recessive Forms of BEST Disease ...

A routine experiment with a new single-cell DNA sequencing method turned into a surprising scientific twist when researchers ...

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) can have the same genetic cause, a discovery that won ...

In Mendelian inheritance patterns, you receive one version of a gene, called an allele, from each parent. These alleles can be dominant or recessive. Non-Mendelian genetics don’t completely follow ...

Cancer isn't a static target. Its genetic profile can change. So even with the newer targeted therapies, a patient's care ...

Full-year 2026 guidance assumes a stronger second half, driven by the productivity of 100 newly hired account executives and ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) in Q1 CY2026 as sales rose 2.3% year on year to $200.4 million. On the ...